Results pending
Arbaclofen placarbil: improve symptoms or function in relapsing and progressive MS
relapsing and progressive MS · Spasticity
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 228
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 1
These linked trials do not set the status.
- Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisNo result found
Phase 3 · 2011 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Results pending
Related hypotheses
- Spasticity: improve symptoms or function in relapsing and progressive MS
- Arbaclofen: improve symptoms or function in relapsing and progressive MS
- Botulinum toxin type a: improve symptoms or function in relapsing and progressive MS
- Cannabidiol: improve symptoms or function in relapsing and progressive MS
- Dronabinol: improve symptoms or function in relapsing and progressive MS
- Nabiximols: improve symptoms or function in relapsing and progressive MS
- Onabotulinumtoxina: improve symptoms or function in relapsing and progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error